Celltrion Chairman Seo Jung-jin announced at a startup event held at COEX in Samseong-dong, Seoul on June 23 that Celltrion will conduct a human clinical trial of a new coronavirus infection (COVID-19) treatment drug on July 16.
"Celltrion will start clinical trials on monkeys after completing the COVID-19 hamster clinical trial," Said Chairman Seo as a speaker of the event. "When the company finish the animal clinical trial, it will start clinical trials on July 16."
In March, Chairman Seo announced his plan to conduct human clinical trials of COVID-19 antibody treatment candidate materials by the end of July at the latest.
"We plan to complete the licensing process in the first quarter of next year after completing this year`s clinical trials," Seo said. "We plan to produce a total of 5 million doses of COVID-19 treatments next year and supply 1 million of them for Korea and 4 million for overseas."
Meanwhile, Chairman Seo predicted that the COVID-19 pandemic will continue until the end of next year.
